Henry E. Schea
President at Genopoietic SA
Profile
Henry E.
Schea is currently the President & General Director at Genopoietic SA since 2009.
Prior to this, he worked at AVAX Technologies, Inc. as the Executive Director-Regulatory Affairs from 2011 to 2016.
He completed his undergraduate degree from the University of Massachusetts in 1976.
Henry E. Schea active positions
| Companies | Position | Start |
|---|---|---|
Genopoietic SA
 Genopoietic SA BiotechnologyHealth Technology Part of AVAX Technologies, Inc., Genopoietic SA is a French company that researches and develops cell and gene therapy for cancer, autoimmune diseases, and orthopedics. The company is based in Paris, France. Genopoietic was acquired by AVAX Technologies, Inc. on August 24, 2000 for $198.62 million. | President | 21/10/2011 |
Former positions of Henry E. Schea
| Companies | Position | End |
|---|---|---|
| AVAX TECHNOLOGIES, INC. | General Counsel | 01/04/2016 |
Training of Henry E. Schea
| University of Massachusetts | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| AVAX TECHNOLOGIES, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Genopoietic SA
Genopoietic SA BiotechnologyHealth Technology Part of AVAX Technologies, Inc., Genopoietic SA is a French company that researches and develops cell and gene therapy for cancer, autoimmune diseases, and orthopedics. The company is based in Paris, France. Genopoietic was acquired by AVAX Technologies, Inc. on August 24, 2000 for $198.62 million. | Health Technology |
- Stock Market
- Insiders
- Henry E. Schea
